In short
Crinecerfont, also known as NBI-74788 or Crenessity, is an investigational drug being studied for the treatment of Congenital Adrenal Hyperplasia (CAH). This article explores the ongoing clinical trials evaluating the safety, efficacy, and tolerability of Crinecerfont in both adult and pediatric patients with classic CAH due to 21-hydroxylase deficiency. These trials aim to assess the drug's potential in reducing glucocorticoid doses and improving hormone balance in CAH patients.
At a glance
- Drug Name
- Crinecerfont (NBI-74788, Crenessity)
- Condition Studied
- Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency
- Study Phases
- Phase 2 and Phase 3
- Age Groups
- Adults and Pediatric (14-17 years)
- Administration
- Oral (capsule or solution), twice daily
- Primary Outcomes
- Changes in hormone levels (17-OHP, androstenedione), glucocorticoid dose reduction
- Secondary Outcomes
- Body composition changes, metabolic parameters, menstrual regularity, TART volume
- Study Duration
- Core studies: 14-20 months; Open-label extension: ~3 years
- Mechanism of Action
- CRF type 1 receptor antagonist
What is Crinecerfont?
Crinecerfont, also known by its research name NBI-74788, is a new medication being developed to treat Congenital Adrenal Hyperplasia (CAH). It is currently undergoing clinical trials to evaluate its safety and effectiveness in both adults and children with this condition.
What Condition Does Crinecerfont Treat?
Crinecerfont is specifically designed to treat Congenital Adrenal Hyperplasia (CAH). CAH is a genetic disorder that affects the adrenal glands, which are small glands located on top of the kidneys. In people with CAH, the adrenal glands cannot produce certain hormones properly, particularly cortisol. This leads to an overproduction of male hormones (androgens) and can cause various health issues.
How Does Crinecerfont Work?
Crinecerfont is a CRF1-receptor antagonist. This means it blocks a specific receptor in the body that is involved in the production of certain hormones. By doing so, Crinecerfont aims to reduce the overproduction of androgens (male hormones) in people with CAH. This could potentially help manage the symptoms of the condition and reduce the need for high doses of other medications currently used to treat CAH.
Clinical Trials for Crinecerfont
Crinecerfont is currently being studied in several clinical trials:
- A Phase 2 trial in adolescents (14-17 years old) with CAH
- A Phase 3 trial in adults with classic CAH
- A Phase 3 trial in children with classic CAH
These trials are designed to evaluate the safety, effectiveness, and proper dosing of Crinecerfont in different age groups. They involve both short-term and long-term treatment periods to gather comprehensive data on the medication's effects.
Potential Benefits of Crinecerfont
Based on the clinical trials, researchers are investigating several potential benefits of Crinecerfont for people with CAH:
- Reduction in glucocorticoid dose: Crinecerfont may allow patients to reduce their daily dose of glucocorticoids, which are currently used to treat CAH but can have significant side effects when used long-term
- Improved hormone balance: The medication aims to reduce levels of certain hormones that are typically elevated in CAH, such as androstenedione and 17-hydroxyprogesterone
- Metabolic improvements: Researchers are studying whether Crinecerfont can help improve various metabolic factors, including insulin resistance, body weight, and fat mass
- Other potential benefits: The trials are also investigating effects on blood pressure, glucose tolerance, menstrual regularity in females, and testicular adrenal rest tumors in males
How is Crinecerfont Administered?
In the clinical trials, Crinecerfont is being administered orally (by mouth). It is given twice daily, either as a capsule or as a solution. The exact dosage and formulation may vary depending on the age of the patient and the specific trial.
It's important to note that Crinecerfont is still an investigational drug. This means it has not yet been approved by regulatory agencies like the FDA for general use. Its safety and effectiveness are still being studied, and it is only available to patients participating in clinical trials.